Health Policy and Economics
The Department's research agenda aims not only to generate evidence, but also to explore its implications and uses for policies on medical research, the funding and regulation of care, payment to providers, and other variables that shape the ability of health care systems, Western and other, to sustain affordable universal coverage and high quality care. Our large dataset analysis has focused on important policy challenges, such as volume-outcome relationships, readmission models, and learning curves. Our economic research is mostly centered on cost-effectiveness analysis.
One area of strength for the Department is its expertise in US and international biomedical science and technology policies. We are among a small handful of academic medical center Departments nationwide to focus on policy issues along the entire spectrum of medical innovation, from basic research to clinical application. Our research and training activities aim to bring quantitative, qualitative and historical evidence to bear on issues such as the allocation of resources for science and technology, how regulatory and funding policies affect the rate and direction of technological change, the effectiveness of organizational models for innovation, and the productivity of the clinical research enterprise. The Department's research has contributed to the national dialogue on how the inability of the U.S. clinical trials enterprise to keep pace with the advances in biomedical research limits society's ability to realize the clinical benefits of scientific discovery. One important policy activity was a Mount Sinai based conference, co-sponsored by the IOM, Conduits and the Department, that addressed challenges and potential solutions for improving the productivity of US clinical trials through public engagement (Institute of Medicine (IOM).2012. Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary. Washington, DC: The National Academies Press.
One of our strengths is our ability to analyze the cost effectiveness of clinical interventions and health programs. Our work has focused on ventricular support devices, prostate cancer, hospital acquired infections and vaccine programs.
Melissa Chase, MPA
Executive Assistant II